Arovella Therapeutics Limited has disclosed its corporate governance policies and practices in its latest Corporate Governance Statement. The company has outlined several key governance measures, including a diversity policy, a code of conduct for directors, senior executives, and employees, and a whistleblower policy. Additionally, Arovella has disclosed its anti-bribery and corruption policy and informed the board of any material breaches.
Material actions and disclosures
Arovella has also disclosed its values and a board skills matrix, as well as a continuous disclosure compliance policy and an investor relations program. The company has also disclosed whether it has any material exposure to environmental and social risks and how it manages or intends to manage those risks.
Forward commitments
Arovella has committed to reviewing its risk management framework at least annually and disclosing the fact that it does not have an internal audit function or a nomination committee. The company has also committed to disclosing the processes employed for evaluating and continually improving the effectiveness of its risk management and internal control processes.